Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors

Lung Cancer

Volumn 86, Issue 2, 2014, Pages 241-246

  Chong, Curtis R ^a   Wirth, Lori J ^b   Nishino, Mizuki ^c   Chen, Aileen B ^c   Sholl, Lynette M ^c   Kulke, Matthew H ^a   McNamee, Ciaran J ^c   Jänne, Pasi A ^a   Johnson, Bruce E ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Atypical carcinoid; DIPNECH; Typical carcinoid

Indexed keywords

ETOPOSIDE; OCTREOTIDE; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMORADIOTHERAPY; ADRENAL METASTASIS; ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; COUGHING; CUSHING SYNDROME; DRUG EFFICACY; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTATIC PULMONARY CARCINOID TUMOR; MULTIMODALITY CANCER THERAPY; MULTIPLE ENDOCRINE NEOPLASIA; PANCREAS METASTASIS; PNEUMONIA; PROGRESSION FREE SURVIVAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; SMOKING; SPLEEN METASTASIS; THORAX RADIOGRAPHY; TREATMENT RESPONSE; CARCINOID TUMOR; LUNG NEOPLASMS; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOID TUMOR; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84908399268     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.08.012     Document Type: Article

References (34)

1. Rekhtman N. Neuroendocrine tumors of the lung: an update. Arch Pathol Lab Med 2010, 134:1628-1638.
2. Travis W.D. Advances in neuroendocrine lung tumors. Ann Oncol 2010, 21(Suppl. 7):vii65-vii71.
3. Travis W.D., Rush W., Flieder D.B., Falk R., Fleming M.V., Gal A.A., et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 1998, 22:934-944.
4. Garcia-Yuste M., Matilla J.M., Cueto A., Paniagua J.M., Ramos G., Canizares M.A., et al. Typical and atypical carcinoid tumours: analysis of the experience of the Spanish Multi-centric Study of Neuroendocrine Tumours of the Lung. Eur J Cardiothorac Surg 2007, 31:192-197.
5. Cao C., Yan T.D., Kennedy C., Hendel N., Bannon P.G., McCaughan B.C. Bronchopulmonary carcinoid tumors: long-term outcomes after resection. Ann Thorac Surg 2011, 91:339-343.
6. Chen F., Sato T., Fujinaga T., Sakai H., Miyahara R., Bando T., et al. Surgical management of bronchopulmonary typical carcinoid tumors: an institutional experience. Interact Cardiovasc Thorac Surg 2010, 11:737-739.
7. Machuca T.N., Cardoso P.F., Camargo S.M., Signori L., Andrade C.F., Moreira A.L., et al. Surgical treatment of bronchial carcinoid tumors: a single-center experience. Lung Cancer 2010, 70:158-162.
8. Wirth L.J., Carter M.R., Janne P.A., Johnson B.E. Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy. Lung Cancer 2004, 44:213-220.
9. Jett J.R., Carr L.L. Systemic treatment of advanced lung carcinoid tumors: show me the data!. Chest 2013, 143:884-886.
10. Buonerba C., Gallo C., Di Lorenzo G., Romeo V., Marinelli A. Ten-year adjuvant treatment with somatostatin analogs in a patient with atypical carcinoid of the lung. Anticancer Drugs 2010, 21:465-468.
11. Masi G., Fornaro L., Cupini S., Loupakis F., Vasile E., Baldi G.G., et al. Refractory neuroendocrine tumor-response to liposomal doxorubicin and capecitabine. Nat Rev Clin Oncol 2009, 6:670-674.
12. Fury M.G., Sherman E., Haque S., Korte S., Lisa D., Shen R., et al. A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors. Cancer Chemother Pharmacol 2012, 69:591-598.
13. Fazio N., Granberg D., Grossman A., Saletan S., Klimovsky J., Panneerselvam A., et al. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study. Chest 2013, 143:955-962.
14. Arriagada R., Bergman B., Dunant A., Le Chevalier T., Pignon J.P., Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004, 350:351-360.
15. Pignon J.P., Tribodet H., Scagliotti G.V., Douillard J.Y., Shepherd F.A., Stephens R.J., et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008, 26:3552-3559.
16. Douillard J.Y., Rosell R., De Lena M., Carpagnano F., Ramlau R., Gonzales-Larriba J.L., et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006, 7:719-727.
17. Pavel M.E., Hainsworth J.D., Baudin E., Peeters M., Horsch D., Winkler R.E., et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011, 378:2005-2012.
18. Florez J.C., Shepard J.A., Kradin R.L. Case records of the Massachusetts General Hospital. Case 17-2013. A 56-year-old woman with poorly controlled diabetes mellitus and fatigue. N Engl J Med 2013, 368:2126-2136.
19. Sachithanandan N., Harle R.A., Burgess J.R. Bronchopulmonary carcinoid in multiple endocrine neoplasia type 1. Cancer 2005, 103:509-515.
20. Kruger S., Buck A.K., Blumstein N.M., Pauls S., Schelzig H., Kropf C., et al. Use of integrated FDG PET/CT imaging in pulmonary carcinoid tumours. J Intern Med 2006, 260:545-550.
21. Kuyumcu S., Adalet I., Sanli Y., Turkmen C., Ozkan Z.G., Yilmazbayhan D. Somatostatin receptor scintigraphy with 111In-octreotide in pulmonary carcinoid tumours correlated with pathological and 18FDG PET/CT findings. Ann Nucl Med 2012, 26:689-697.
22. Crona J., Fanola I., Lindholm D.P., Antonodimitrakis P., Oberg K., Eriksson B., et al. Effect of temozolomide in patients with metastatic bronchial carcinoids. Neuroendocrinology 2013, 98:151-155.
23. Filosso P.L., Ruffini E., Oliaro A., Papalia E., Donati G., Rena O. Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide. Eur J Cardiothorac Surg 2002, 21:913-917.
24. Corleto V.D., Angeletti S., Schillaci O., Marignani M., Caratozzolo M., Panzuto F., et al. Long-term octreotide treatment of metastatic carcinoid tumor. Ann Oncol 2000, 11:491-493.
25. Gandhi L., Camidge D.R., Ribeiro de Oliveira M., Bonomi P., Gandara D., Khaira D., et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 2011, 29:909-916.
26. Merle-Vincent F., Chevrel G., Lombard-Bohas C., Felmann C., Meunier P.J. Bone metastases from bronchial carcinoid tumors. Two case-reports. Rev Rhum Engl Ed 1999, 66:46-48.
27. Kon T., Hara N., Su M., Takahashi H. Multiple brain metastasis of bronchial atypical carcinoid: unusual MR imaging, case report. No Shinkei Geka 1997, 25:815-818.
28. Canizares M.A., Garcia-Fontan E.M., Rivo J.E., Gonzalez-Pineiro A. Local recurrence and metastatic disease in a typical N1 carcinoid bronchial tumour. Clin Transl Oncol 2005, 7:216-218.
29. Mokuno Y., Katoh T., Yoshida K., Kamiya S., Chigira H., Maeda M. Liver metastasis nineteen years after surgery for typical bronchial carcinoid. Hepatogastroenterology 1999, 46:2961-2964.
30. Nassar A.A., Jaroszewski D.E., Helmers R.A., Colby T.V., Patel B.M., Mookadam F. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: a systematic overview. Am J Respir Crit Care Med 2011, 184:8-16.
31. Akashiba T., Matsumoto K., Kosaka N., Saito O., Horie T., Nemoto N. Multifocal peripheral bronchial carcinoid tumour. Respirology 1999, 4:199-201.
32. Aubry M.C., Thomas C.F., Jett J.R., Swensen S.J., Myers J.L. Significance of multiple carcinoid tumors and tumorlets in surgical lung specimens: analysis of 28 patients. Chest 2007, 131:1635-1643.
33. Beshay M., Roth T., Stein R., Schmid R.A. Synchronous bilateral typical pulmonary carcinoid tumors. Eur J Cardiothorac Surg 2003, 23:251-253.
34. Yazici U., Gulhan E., Agackiran Y., Tastepe I., Yaran P. Synchronous bilateral multiple typical pulmonary carcinoid tumors. Ann Thorac Surg 2010, 89:1278-1280.